Allervie Clinical Research | Homewood, AL

Research site
504 Brookwood Boulevard Suite 250, Birmingham, Alabama, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


12 of 14
Status: Active
Trial type: Interventional
Funder type: Industry

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (HAErmony-1)

This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due...

Hereditary Angioedema
Genetic: Dose 6 of BMN 331
Genetic: Dose 2 of BMN 331

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.

Eosinophilic Esophagitis
Drug: Matching Placebo
Biological: barzolvolimab

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1...

Hereditary Angioedema
Drug: STAR-0215

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Chronic Obstructive Pulmonary Disease (COPD)
Drug: Placebo
Drug: Astegolimab

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Moderate to Severe Asthma
Drug: povorcitinib
Other: placebo
Locations recently updated

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Chronic Inducible Urticaria
Other: Placebo
Drug: Remibrutinib

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody re...

Dermatitis Atopic
Drug: Placebo
Biological: PPS vaccine
Locations recently updated

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Atopic Dermatitis
Other: Placebo
Drug: PF-07264660

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: LOU064 (open label)

This is an extension study to evaluate the long-term safety and efficacy of ligelizumab in particiants who have completed a ligelizumab Phase III stu...

Food Allergy
Drug: Ligelizumab 240 mg
Drug: Ligelizumab 120 mg

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Chronic Spontaneous Urticaria
Drug: Oral EP262
Drug: Placebo

This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis

Atopic Dermatitis
Drug: Placebo
Drug: Oral EP262

Trial conditions

Urticaria (4 trials)
Atopic Dermatitis (3 trials)
Chronic Urticaria (3 trials)
Dermatitis (3 trials)
Angioedema (2 trials)
Eczema (2 trials)
Hereditary Angioedemas (2 trials)
Hypersensitivity (2 trials)
Asthma (1 trial)
Chronic Inducible Urtica... (1 trial)

And 7 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems